IGM Biosciences Announces Q3 2024 Financial Results & Update
08 Nov 2024 //
GLOBENEWSWIRE
IGM Biosciences to Present at Three Upcoming Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
IGM Biosciences Shifts Focus Exclusively To Autoimmunity
30 Sep 2024 //
GLOBENEWSWIRE
IGM Biosciences To Present At Stifel Immunology Summit
10 Sep 2024 //
GLOBENEWSWIRE
IGM Biosciences Announces Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
IGM Biosciences to Present at the Jefferies Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
IGM Biosciences Q1 2024 Financials, Corporate Update
08 May 2024 //
GLOBENEWSWIRE
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
07 May 2024 //
GLOBENEWSWIRE
IGM Biosciences Shares Up 13.7%
28 Apr 2024 //
DEFENSWORLD
IGM Biosciences Refocuses Sanofi Collaboration
17 Apr 2024 //
GLOBENEWSWIRE
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10 Apr 2024 //
GLOBENEWSWIRE
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
IGM Bio to Present at the Healthcare Talks 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
IGM Bio Announces Strategic Pipeline Prioritization and Cash Runway Extension
05 Dec 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
IGM Biosciences to Present at Two Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
IGM Announces Retirement of Chairman Michael Loberg from Board of Directors
03 Oct 2023 //
GLOBENEWSWIRE
IGM to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 Sep 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
IGM Announces Closing of Upsized Public Offering & Concurrent Private Placement
03 Jul 2023 //
GLOBENEWSWIRE
IGM Announces Pricing of $107.3 Million Upsized Public Offering
22 Jun 2023 //
GLOBENEWSWIRE
Biotechs launch public offerings; Vaxxinity shares data on Parkinson`s vaccine
22 Jun 2023 //
ENDPTS
IGM Announces Proposed Public Offering and Concurrent Private Placement
21 Jun 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial
02 Jun 2023 //
GLOBENEWSWIRE
FDA clears IGM Biosciences’ INDs for SLE and RA therapy trials
01 Jun 2023 //
CLINICAL TRIALS ARENA
IGM Biosciences to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab
31 May 2023 //
GLOBENEWSWIRE
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 update
30 May 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
IGM Biosciences to Present at Two Upcoming Investor Conferences
02 May 2023 //
GLOBENEWSWIRE
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
19 Apr 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces Six Presentations at AACR Annual Meeting 2023
13 Apr 2023 //
GLOBENEWSWIRE
IGM Biosciences Announces 4Q and Reports 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
02 Feb 2023 //
GLOBENEWSWIRE
IGM Biosciences Initiates First-in-Human Trial of IGM-7354 in Solid Tumors
17 Jan 2023 //
GLOBENEWSWIRE
IGM Announces Update on IGM-8444 PI Trial and Future Clinical Development
09 Jan 2023 //
GLOBENEWSWIRE
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
IGM Presents Data from T cell Engager Portfolio for Hematologic Malignancies
11 Dec 2022 //
PRESS RELEASE
IGM Presents Data from T cell Engager Portfolio for Hematologic Malignancies
11 Dec 2022 //
GLOBENEWSWIRE
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
01 Dec 2022 //
GLOBENEWSWIRE
IGM Biosciences Announces 3Q FYR and Provides Corporate Update
03 Nov 2022 //
GLOBENEWSWIRE
IGM & ADC Announce Clinical Collaboration Agreement to Evaluate Imvotamab
02 Nov 2022 //
PRESS RELEASE
IGM Biosciences to Present at Three Upcoming Investor Conferences
06 Sep 2022 //
GLOBENEWSWIRE
IGM Biosciences Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
IGM Biosciences to Present at the 2022 RBC Capital Markets
10 May 2022 //
GLOBENEWSWIRE
IGM Biosciences Announces First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi
06 May 2022 //
GLOBENEWSWIRE
IGM Announces Closing of $230.0 Million Public Offering
06 Apr 2022 //
GLOBENEWSWIRE
IGM Announces Pricing of $200.0 Million Public Offering
30 Mar 2022 //
GLOBENEWSWIRE
Why IGM Biosciences Stock Rocketed Higher Today
29 Mar 2022 //
MOTLEY FOOL
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
IGM Announces Proposed Public Offering
29 Mar 2022 //
GLOBENEWSWIRE
Paul Hudson spells out new $6.15B technology play with Sanofi
29 Mar 2022 //
ENDPTS
IGM Biosciences Advances IGM-6268 Into Clinical Trials for COVID-19
09 Feb 2022 //
GLOBENEWSWIRE
IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference
03 Feb 2022 //
GLOBENEWSWIRE
IGM Bio Presents Clinical Data from IGM-2323 in B Cell Tumors
11 Dec 2021 //
PRESS RELEASE
IGM Bio to Collaborate on Study of IgM and IgA Antibodies
08 Dec 2021 //
PRESS RELEASE
IGM Bio to Review IGM-2323 Data in a Webcast and Conference
06 Dec 2021 //
PRESS RELEASE